,

Ye Wang1,2, Yingqiu Song1, Runze Wang1

  • 1Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, China.

Frontiers in oncology
|April 29, 2024
PubMed
概括

在接受新辅助化疗免疫疗法 (NCIO) 的肺平细胞癌 (LUSC) 患者中,主要病理反应 (MPR) 由治疗前的淋巴细胞水平,瘤负担,N分类,放射性反应,肺 atelectasis 和 PD-L1 表达预测. 一个名图模型准确地预测了MPR,改善了LUSC的个性化治疗.